UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: August 2025

Commission file number: 001-41557

CLEARMINDMEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annualreports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is theRegistrant’s press release issued on August 7, 2025, titled “Clearmind Medicine Announces Publication of International PatentApplication for Novel Combination Therapy Targeting Obesity and High Blood Sugar”.

The first four paragraphsof the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s RegistrationStatements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293)and Form S-8 (File No. 333-283695),filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extentnot superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

SIGNATURES

Pursuant to the requirementsof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereuntoduly authorized.

Exhibit 99.1

Clearmind Medicine Announces Publication ofInternational Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Vancouver, Canada, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind MedicineInc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discoveryand development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publicationof an international patent application under the Patent Cooperation Treaty (PCT) as part of its ongoing collaboration with SciSparc Ltd.(Nasdaq: SPRC) (“SciSparc”), a specialty clinical-stage pharmaceutical company developing therapies for central nervous systemdisorders.

The patent application published under the European Patent Office coversan innovative combination therapy of Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) and SciSparc’s Palmitoylethanolamide(PEA) for the treatment of metabolic syndrome and obesity.

Metabolic syndrome, characterized by conditions such as high bloodpressure, high blood sugar, excess abdominal fat, and elevated cholesterol levels, affects up to one-third of U.S. adults and increasesthe risk of heart disease, stroke, obesity and type 2 diabetes. This proprietary combination therapy leverages MEAI’s unique pharmacologicalprofile alongside PEA’s anti-inflammatory and neuroprotective properties to offer a potential safe and effective treatment for thesewidespread health challenges.

This patent publication marks a significant milestone in the Clearmind-SciSparccollaboration, which has resulted in the filing of 13 patent families, across multiple jurisdictions, such as the United States, Europe,and China. The collaboration focuses on developing innovative therapies that combine neuroplastogens molecules with N-acylethanolamines,including PEA, to address mental health disorders such as depression and PTSD, addictions, and various metabolic conditions and obesity.

Dr. Adi Zuloff-Shani, CEO of Clearmind, stated:“We continue our strategy to develop breakthrough therapies to treat complex health conditions, with our intellectual propertyportfolio enabling us to potentially redefine therapeutic approaches for metabolic syndrome and obesity, leveraging, among others, thesynergistic effects of MEAI and PEA.”

About Clearmind Medicine Inc.

Clearmind is a clinical-stage psychedelic pharmaceutical biotech companyfocused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems,including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercializethem as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of nineteenpatent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted andwill remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol“CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”

For further information visit: https://www.clearmindmedicine.com orcontact:

Investor Relations
invest@clearmindmedicine.com

Telephone: (604) 260-1566
US: CMND@crescendo-ir.com

General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-lookingstatements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,”“anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates”and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is usingforward-looking statements when it discusses its strategy to develop breakthrough therapiesto treat complex health conditions and how its intellectual property portfolio enables it to potentially redefine therapeutic approachesfor metabolic syndrome and obesity, leveraging, among others, the synergistic effects of MEAI and PEA .  The Company cannot assurethat any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageousto the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefsand projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed ingood faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, andactual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statementsare subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in theforward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is madeto the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, butnot limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 andsubsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes noobligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptionsor changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If theCompany does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updateswith respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience,and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsiblefor the contents of third-party websites.